Analyst Price Targets — HRMY
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 23, 2026 11:37 am | — | Deutsche Bank | $31.00 | $29.16 | TheFly | Harmony Biosciences downgraded to Hold from Buy at Deutsche Bank |
| February 19, 2026 12:17 pm | — | Mizuho Securities | $50.00 | $35.28 | TheFly | Harmony Biosciences price target raised to $50 from $46 at Mizuho |
| February 11, 2026 12:28 pm | Youn Shim | UBS | $46.00 | $37.93 | TheFly | Harmony Biosciences assumed at Neutral from Buy at UBS |
| January 8, 2026 12:54 pm | — | Truist Financial | $45.00 | $37.55 | TheFly | Harmony Biosciences price target lowered to $45 from $48 at Truist |
| December 1, 2025 11:56 am | — | Mizuho Securities | $46.00 | $35.29 | TheFly | Harmony Biosciences price target raised to $46 from $39 at Mizuho |
| November 24, 2025 9:40 am | Andreas Argyrides | Oppenheimer | $62.00 | $34.31 | StreetInsider | Oppenheimer Reiterates Outperform Rating on Harmony Biosciences Holdings Inc. (HRMY) Post Mgmt Meet |
| October 29, 2025 12:50 pm | — | Mizuho Securities | $36.00 | $29.64 | TheFly | Harmony Biosciences price target raised to $36 from $35 at Mizuho |
| October 15, 2025 11:07 am | — | UBS | $43.00 | $26.85 | TheFly | Harmony Biosciences price target lowered to $43 from $50 at UBS |
| September 25, 2025 10:11 am | — | H.C. Wainwright | $55.00 | $27.04 | TheFly | Harmony Biosciences price target lowered to $55 from $70 at H.C. Wainwright |
| July 10, 2025 9:08 am | Corinne Johnson | Goldman Sachs | $33.00 | $34.33 | TheFly | Harmony Biosciences resumed with a Neutral at Goldman Sachs |
Latest News for HRMY
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will present encore open-label extension data from the company's investigation of EPX-100 (clemizole hydrochloride) in the ongoing Phase 3 ARGUS trial for the treatment of Dravet syndrome at the 2026 American Academy of Neurology Annual Meeting being held April 18 – 22 in Chicago, IL. The ARGUS trial is…
Harmony Biosciences (NASDAQ: HRMY) executives outlined 2026 priorities at Needham and Company's Virtual Healthcare Conference, emphasizing continued growth for WAKIX and multiple late-stage pipeline readouts across sleep-wake and rare epilepsy indications. WAKIX outlook and commercial execution President and CEO Jeffrey Dayno said Harmony is "on track to achieve over $1 billion in net revenue for WAKIX
Harmony Biosciences Holdings, Inc. (HRMY) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced the appointment of Glenn Reicin as Chief Financial Officer, effective immediately, supporting Harmony's continued focus on strategic growth, financial strength, and long‑term value creation. Harmony is also reiterating its 2026 net product revenue guidance of $1.0 to $1.04 billion. Mr. Reicin is a seasoned…
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced the appointment of Peter Anastasiou as Chief Operating Officer and updates to its Board of Directors, including the appointment of Troy Ignelzi as a director and the nomination of Geno J. Germano as a director for election at Harmony's 2026 Annual Meeting of Shareholders. Mr. Anastasiou previously served on…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for HRMY.
U.S. House Trading
No House trades found for HRMY.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.